Evidence map›Paper›PMID 40721855›Full record

ArticleScientific reports2025

Unveiling the impact of OVOL1 on prognosis, immune microenvironment, and proliferation in pancreatic cancer.

Jinping Li, Zhenyan Deng, Zhaofang Yan, Shuxian Huang, Jiamin Jin, Chichu Xie, Jinfeng Gan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jinping Li *Department of Histology and Embryology, School of Preclinical Medicine, Guilin Medical University, Guilin, China.
Zhenyan Deng *Department of Clinical Laboratory, Guilin Hospital of the Second Xiangya Hospital of Central South University, Guilin, China.
Zhaofang YanGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Shuxian HuangGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Jiamin JinGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Chichu XieGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China.
Jinfeng GanGuangxi Key Laboratory of Tumor Immunology and Microenvironmental Regulation, Guilin Medical University, Guilin, China. jinfenggan@glmc.edu.cn.

Funding

Guangxi Natural Science Foundation 2023GXNSFAA026061Guangxi Natural Science Foundation 2025GXNSFAA069430Guangxi Natural Science Foundation 2025GXNSFAA069949Guangxi Science and Technology Program GuiKe AD23026143National Natural Science Foundation of China 32360170National Natural Science Foundation of China 82160590National Natural Science Foundation of China 82460546
6 · The paper itself

Abstract

OVO-like protein 1 (OVOL1) has been implicated in the progression of various human cancers; however, the prognostic and immunological significance, as well as its biological role in pancreatic cancer, are unknown. In this study, by analyzing multiple patient cohorts, OVOL1 was found to be elevated in pancreatic cancer, which was associated with poor overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). Two nomogram survival models for predicting 1-, 2-, and 3-year OS and DSS with excellent accuracy were constructed, respectively. Tumors with elevated OVOL1 expression showed decreased immune cell infiltration, including CD8 T cells, NK cells, and cytotoxic cells, and increased tumor mutation burden (TMB). Enrichment analysis revealed that OVOL1 was related to various biological terms and signaling pathways. Knockdown of OVOL1 reduced the proliferation of pancreatic cancer cells and inhibited the ERK/JNK/p38 MAPK signaling pathway. Furthermore, OVOL1 was revealed to be hypomethylated in pancreatic cancer, with low levels of OVOL1 methylation predicting poor outcomes. Our findings suggest that upregulation of OVOL1 has prognostic value and is associated with the unfavorable immune microenvironment in pancreatic cancer. OVOL1 is crucial for pancreatic cancer cell proliferation, which could be attributed to its effect on the ERK/JNK/p38 MAPK signaling pathway.

Indexed as

Pancreatic NeoplasmsTumor MicroenvironmentBiomarkers, TumorCell Line, TumorCell ProliferationDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorImmune microenvironmentMAPK signaling pathwayOVOL1Pancreatic cancerPrognosisProliferation

Identifiers

PMID40721855
PMCPMC12304111

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.